Ono

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.

ParaZero Customer Speedbird Aero Celebrates 10,000 Operational Delivery Flights, Protected by ParaZero SafeAir Parachute Recovery Systems

Retrieved on: 
Monday, August 21, 2023

What makes this achievement even more remarkable is the unmatched safety and reliability ensured by the integration of mission-critical drone technologies, including ParaZero's cutting-edge SafeAir parachute recovery systems throughout Speedbird Aero's delivery drone fleet.

Key Points: 
  • What makes this achievement even more remarkable is the unmatched safety and reliability ensured by the integration of mission-critical drone technologies, including ParaZero's cutting-edge SafeAir parachute recovery systems throughout Speedbird Aero's delivery drone fleet.
  • Samuel Salomao, Speedbird’s Chief Product Officer, commented: "Our partnership with ParaZero has been instrumental in achieving this significant milestone of 10,000 operational delivery flights.
  • “Speedbird Aero is a global leading player in aerial logistics, and continues to demonstrate their world-class capabilities through various drone delivery initiatives around the world.
  • With Speedbird Aero's extensive utilization of the SafeAir system, they have showcased an unwavering commitment to maintaining the highest safety standards in their delivery operations, as well as the robustness and reliability of the ParaZero SafeAir parachute system.

Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.
  • In April 2023, we received a payment of $4 million from Roche for additional revisions to the clinical development plan under the Roche Agreement.
  • The article, entitled “Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results” can be accessed here .
  • Second Quarter 2023 Financial Results:
    Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of June 30, 2023 were $280.7 million, which Repare believes will be sufficient to fund its planned operations into 2026.

Ono Hawaiian BBQ Celebrates National Spam Musubi Day with Promotions and Giveaways

Retrieved on: 
Wednesday, August 2, 2023

LOS ANGELES, Aug. 2, 2023 /PRNewswire/ -- Ono Hawaiian BBQ is celebrating National Spam Musubi Day on Tuesday, August 8, with a deal and giveaway for its customers. A popular dish introduced in the 1940s, Spam Musubi is a savory Hawaiian snack staple, consisting of grilled Spam, teriyaki sauce and steamed rice wrapped in seaweed.

Key Points: 
  • Say Aloha to 50% off Spam Musubi and a special giveaway on Tuesday, August 8th
    LOS ANGELES, Aug. 2, 2023 /PRNewswire/ -- Ono Hawaiian BBQ is celebrating National Spam Musubi Day on Tuesday, August 8, with a deal and giveaway for its customers.
  • A popular dish introduced in the 1940s, Spam Musubi is a savory Hawaiian snack staple, consisting of grilled Spam, teriyaki sauce and steamed rice wrapped in seaweed.
  • "We enjoy bringing traditional fast-fresh Hawaiian cuisine to our customers and are excited to offer special promotions this Spam Musubi Day for all of our locations."
  • In addition, customers who participate in the Ono Hawaiian BBQ Spam Musubi deal will automatically be entered in the Ono x Spam giveaway.

Global Peptide Cancer Drug Market, Dosage, Price, Sales and Clinical Trials Insight to 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 10, 2023

Global Peptide Drug Market Opportunity: > USD 15 Billion

Key Points: 
  • Global Peptide Drug Market Opportunity: > USD 15 Billion
    Marketed Cancer Peptides Drugs Dosage, Patentand Price Insight
    Marketed Cancer Peptides Drugs Clinical and Commercial Insight: 25 Drugs
    Peptide Cancer Drug Clinical Trials Insight: > 200 Drugs
    Global Peptide Cancer Drug Clinical Trials Insight By Company, Country Indication and Phase
    Biologics have been an important class of drugs for several diseases including cancer.
  • For a long time, peptides have been used as therapeutic agents; however, their potential in cancer has been a new area of interest.
  • Due to their ability to offer advanced optimization strategies, peptide drugs have become an attractive area of research.
  • This will provide diverse market opportunities for each and every therapeutic peptide product candidate.

NEP Group Appoints CFO Martin Stewart as CEO

Retrieved on: 
Thursday, June 8, 2023

NEP Group , the leading worldwide technical production partner supporting premier producers of live sports and entertainment, announced today that Chief Financial Officer Martin Stewart has been appointed Chief Executive Officer.

Key Points: 
  • NEP Group , the leading worldwide technical production partner supporting premier producers of live sports and entertainment, announced today that Chief Financial Officer Martin Stewart has been appointed Chief Executive Officer.
  • His deep transformation insight and experience has helped NEP identify new growth and efficiency opportunities during his time as CFO.
  • His deep transformation insight and experience has helped NEP identify new growth and efficiency opportunities during his time as CFO.
  • Undoubtedly, NEP Group has a bright future ahead.”
    The company is also pleased to announce that, effective immediately, Doug Kovach will be promoted to the role of CFO, NEP Group.

INA, ESR, and Mitsubishi Corporation Join Forces to Unlock the Potential of Indonesia's Modern Warehouse Investment Opportunities

Retrieved on: 
Monday, May 29, 2023

This marks the first milestone towards a broader long-term collaboration aimed at unlocking the vast potential of investing in the development of modern warehouse facilities in Indonesia.

Key Points: 
  • This marks the first milestone towards a broader long-term collaboration aimed at unlocking the vast potential of investing in the development of modern warehouse facilities in Indonesia.
  • The demand for modern warehouse facilities in Indonesia is driven by key sectors, including e-commerce, third-party logistics (3PL), and the automotive industries.
  • At present, the Indonesian warehouse market, stands at around 29 million sqm, with modern warehouses only accounting for approximately 8% of the total market.
  • This collaboration aims to seize this opportunity to invest in modern warehouse assets and secure a substantial share of this expanding market.

Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer

Retrieved on: 
Tuesday, May 16, 2023

Under the agreement, National Cancer Center Hospital East (NCCHE) will recruit patients and conduct the clinical trial, Ono will provide nivolumab, and Personalis will perform MRD and biomarker testing.

Key Points: 
  • Under the agreement, National Cancer Center Hospital East (NCCHE) will recruit patients and conduct the clinical trial, Ono will provide nivolumab, and Personalis will perform MRD and biomarker testing.
  • Biomarker research will be conducted throughout the study, including sample analysis from both tumor lesion tissue and plasma circulating tumor DNA (ctDNA).
  • Tissue samples will be analyzed by the Personalis ImmunoID NeXT ® platform to capture tumor molecular profile and tumor microenvironment features to better understand immunotherapy responses.
  • These comprehensive assays may enable the selection of cases with high efficacies and will promote the non-operative management in dMMR rectal cancer.”

Kanazawa University research: Zooming in on neurotoxic aggregates

Retrieved on: 
Thursday, May 11, 2023

KANAZAWA, Japan, May 11, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy leads to insights into processes relevant to Alzheimer's disease.

Key Points: 
  • KANAZAWA, Japan, May 11, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy leads to insights into processes relevant to Alzheimer's disease.
  • In particular, intermediate aggregates such as protofibrils are more toxic than the actual final fibrils, the main component of Aβ plaques.
  • Kenjiro Ono from Kanazawa University and colleagues have now succeeded in visualizing the structural dynamics of protofibrils, as well as the effect of a recently developed drug based on anti-Aβ antibodies.
  • Researchers at Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.

Kanazawa University research: Zooming in on neurotoxic aggregates

Retrieved on: 
Thursday, May 11, 2023

KANAZAWA, Japan, May 11, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy leads to insights into processes relevant to Alzheimer's disease.

Key Points: 
  • KANAZAWA, Japan, May 11, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy leads to insights into processes relevant to Alzheimer's disease.
  • In particular, intermediate aggregates such as protofibrils are more toxic than the actual final fibrils, the main component of Aβ plaques.
  • Kenjiro Ono from Kanazawa University and colleagues have now succeeded in visualizing the structural dynamics of protofibrils, as well as the effect of a recently developed drug based on anti-Aβ antibodies.
  • Researchers at Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.